Text Size: a  |   a 

Aphios Awarded Grant for Cannaboid Production to Produce MS Agent

September 16, 2015

A green biotechnology company based in Massachusetts named Aphios Corporation announced that it was awarded the Phase 2 portion of a fast track grant from the NIDA for the production of cannabidiol from marijuana. The compound is expected to be an effective agent for Multiple Sclerosis patients, and patients suffering from other CNS (central nervous system) diseases.

Cannabis is a plant employed in diverse settings, which is known to be a source of fibers and oils, as well as a recreational drug. Many studies have found a positive link between cannabis and treatment of medical conditions much like MS.
CBD is one of the active compounds found in cannabis. CBD is the major phytocannabinoid in the plant, representing up to 40% of the plant’s extract. Aphios has developed a research program to establish a process for manufacturing pharmaceutical grade CBD under Good Manufacturing Practices of the US Food and Drug Administration, to be used in clinical trials for several CNS disorders including multiple sclerosis. 

“Marijuana, which contains more than 100 cannabinoids, has been used anecdotally for centuries for diverse medical indications. There have been numerous self-reported cases by patients that smoking marijuana alleviates symptomatology, some of which has been confirmed by numerous studies and surveys.” noted Aphios CEO and Principal Investigator on the grant, Dr. Trevor P. Castor in a news release. “Research suggests that some cannabinoids and analogs have potential therapeutic benefits. We thus have indications that both cannabinoids from nature and our endogenous ‘endocannabinoids’ are valuable products and targets for treating some CNS disorders. The cGMP manufacturing of clinical-grade, natural non-psychotropic cannabinoids from marijuana that impact CNS disorders is significant because it will establish safety and efficacy of standardized, non-psychotropic cannabinoids through rigorous clinical trials, providing benefits to thousands of patients.”